JP2023505298A5 - - Google Patents
Info
- Publication number
- JP2023505298A5 JP2023505298A5 JP2022534215A JP2022534215A JP2023505298A5 JP 2023505298 A5 JP2023505298 A5 JP 2023505298A5 JP 2022534215 A JP2022534215 A JP 2022534215A JP 2022534215 A JP2022534215 A JP 2022534215A JP 2023505298 A5 JP2023505298 A5 JP 2023505298A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cancer
- peptide compound
- composition
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945111P | 2019-12-06 | 2019-12-06 | |
| US62/945,111 | 2019-12-06 | ||
| PCT/CA2020/051686 WO2021108929A1 (en) | 2019-12-06 | 2020-12-07 | Sortilin binding conjugate compounds, compositions and uses thereof for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505298A JP2023505298A (ja) | 2023-02-08 |
| JP2023505298A5 true JP2023505298A5 (https=) | 2023-12-04 |
| JP7811908B2 JP7811908B2 (ja) | 2026-02-06 |
Family
ID=76220889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534215A Active JP7811908B2 (ja) | 2019-12-06 | 2020-12-07 | がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230036041A1 (https=) |
| EP (1) | EP4069309A4 (https=) |
| JP (1) | JP7811908B2 (https=) |
| KR (1) | KR20220113980A (https=) |
| CN (1) | CN114980932B (https=) |
| AU (1) | AU2020395148A1 (https=) |
| CA (1) | CA3160722A1 (https=) |
| IL (1) | IL293553A (https=) |
| WO (1) | WO2021108929A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116731113A (zh) * | 2022-03-01 | 2023-09-12 | 上海智肽生物科技有限公司 | 针对sort1的多肽化合物及其药物偶联物 |
| CN120641133A (zh) * | 2022-11-14 | 2025-09-12 | 瑟瑞技术公司 | 用于刺激抗肿瘤免疫应答的药物缀合物化合物 |
| CN118384289A (zh) * | 2024-04-24 | 2024-07-26 | 青岛科技大学 | 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用 |
| WO2025236098A1 (en) * | 2024-05-16 | 2025-11-20 | Theratechnologies Inc. | Peptide conjugates of maytansinoids and uses thereof |
| WO2026021513A1 (zh) * | 2024-07-25 | 2026-01-29 | 上海湃鸿生物科技有限公司 | 一种多肽药物偶联物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008525033A (ja) * | 2004-12-22 | 2008-07-17 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Ｂ群連鎖球菌 |
| US20100129379A1 (en) * | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| US8147849B2 (en) * | 2009-02-20 | 2012-04-03 | Novartis Ag | Protective antigens for group B Streptococcus hypervirulent strains |
| KR101074936B1 (ko) * | 2009-05-25 | 2011-10-18 | 보령제약 주식회사 | 도세탁셀 주사제용 조성물 및 그의 제조방법 |
| CN101708177B (zh) * | 2009-11-23 | 2012-09-05 | 浙江万马药业有限公司 | 一种含多西他赛的药物组合物及其制备方法 |
| JP6285725B2 (ja) * | 2014-01-16 | 2018-02-28 | ナガセ医薬品株式会社 | エタノールフリードセタキセル医薬組成物 |
| SI3380495T1 (sl) * | 2015-11-24 | 2022-01-31 | Transfert Plus, S.E.C. | Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo |
| SMT202500367T1 (it) * | 2017-02-02 | 2025-11-10 | Amgen Res Munich Gmbh | Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t |
| EP3625245A4 (en) * | 2017-05-24 | 2020-12-16 | Transfert Plus, S.E.C. | PEPTIDIC COMPOUNDS, CONJUGATE COMPOUNDS AND THEIR USES IN THE TREATMENT OF INFLAMMATORY DISEASES |
| CN111465389B (zh) * | 2017-09-07 | 2022-06-21 | 深圳信立泰药业股份有限公司 | 多西他赛共缀物的药物组合物及制备方法 |
-
2020
- 2020-12-07 IL IL293553A patent/IL293553A/en unknown
- 2020-12-07 WO PCT/CA2020/051686 patent/WO2021108929A1/en not_active Ceased
- 2020-12-07 CN CN202080092895.XA patent/CN114980932B/zh active Active
- 2020-12-07 JP JP2022534215A patent/JP7811908B2/ja active Active
- 2020-12-07 KR KR1020227022530A patent/KR20220113980A/ko active Pending
- 2020-12-07 CA CA3160722A patent/CA3160722A1/en active Pending
- 2020-12-07 EP EP20895191.3A patent/EP4069309A4/en active Pending
- 2020-12-07 US US17/781,653 patent/US20230036041A1/en active Pending
- 2020-12-07 AU AU2020395148A patent/AU2020395148A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505298A5 (https=) | ||
| JP7573401B2 (ja) | 多リガンド－薬物複合体及びその使用 | |
| AU2020214507B2 (en) | Bi-ligand drug conjugate and use thereof | |
| JP2021535209A5 (https=) | ||
| AU2018387417C1 (en) | Bicyclic peptide ligands specific for EphA2 | |
| US12029736B2 (en) | Camptothecin derivatives and conjugates thereof | |
| AU2020210919B2 (en) | Glycoside-containing peptide linkers for antibody-drug conjugates | |
| EP4043034A9 (en) | Lysosome-targeting antibody-drug conjugate and application thereof | |
| KR101721865B1 (ko) | 항암제의 전달을 위한 폴리머 시스템 | |
| JP2022518695A (ja) | Ｃａｉｘに特異的な二環式ペプチドリガンド | |
| JP2019501141A5 (https=) | ||
| JP2016531583A5 (https=) | ||
| JPWO2018052002A1 (ja) | Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド | |
| CN114980932A (zh) | Sortilin结合缀合化合物、其组合物及其用于治疗癌症的用途 | |
| Zheng et al. | In vivo therapeutic effects of small molecule-drug conjugates enhanced by Fc grafting | |
| EP4297795A1 (en) | Methods and sortilin binding conjugate compounds for targeting cancer stem cells | |
| Tekewe et al. | Proteins and peptides as targeting carriers in anticancer drug delivery: a review | |
| WO2025206033A1 (ja) | ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物 | |
| CN111164094B (zh) | 抗癌肽及其用途 | |
| HK1253921B (en) | Multi-ligand drug conjugates and uses thereof | |
| Vittur | Synthesis, Characterization, and Applications of a Melamine Based Dendrimer with Twelve Cysteine Groups on the Periphery |